BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strid H, Simrén M, Lasson A, Isaksson S, Stridsberg M, Öhman L. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. J Crohns Colitis 2013;7:e615-22. [PMID: 23694857 DOI: 10.1016/j.crohns.2013.04.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Worthington JJ, Reimann F, Gribble FM. Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity. Mucosal Immunol 2018;11:3-20. [DOI: 10.1038/mi.2017.73] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 15.8] [Reference Citation Analysis]
2 Zissimopoulos A, Vradelis S, Konialis M, Chadolias D, Bampali A, Constantinidis T, Efremidou E, Kouklakis G. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol. 2014;49:942-949. [PMID: 24897131 DOI: 10.3109/00365521.2014.920910] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
3 Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742-756. [PMID: 24562174 DOI: 10.1097/01.mib.0000442681.85545.31] [Cited by in Crossref: 99] [Cited by in F6Publishing: 37] [Article Influence: 14.1] [Reference Citation Analysis]
4 Massironi S, Zilli A, Cavalcoli F, Conte D, Peracchi M. Chromogranin A and other enteroendocrine markers in inflammatory bowel disease. Neuropeptides. 2016;58:127-134. [PMID: 26804239 DOI: 10.1016/j.npep.2016.01.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yu Y, Yang W, Li Y, Cong Y. Enteroendocrine Cells: Sensing Gut Microbiota and Regulating Inflammatory Bowel Diseases. Inflamm Bowel Dis 2020;26:11-20. [PMID: 31560044 DOI: 10.1093/ibd/izz217] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
6 Wasinger VC, Yau Y, Duo X, Zeng M, Campbell B, Shin S, Luber R, Redmond D, Leong RW. Low mass blood peptides discriminative of inflammatory bowel disease (IBD) severity: A quantitative proteomic perspective. Mol Cell Proteomics. 2016;15:256-265. [PMID: 26530476 DOI: 10.1074/mcp.m115.055095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
7 Gacesa R, Vich Vila A, Collij V, Mujagic Z, Kurilshikov A, Voskuil MD, Festen EAM, Wijmenga C, Jonkers DMAE, Dijkstra G, Fu J, Zhernakova A, Imhann F, Weersma RK. A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease. Gut Microbes 2021;13:1943288. [PMID: 34313538 DOI: 10.1080/19490976.2021.1943288] [Reference Citation Analysis]
8 Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444-454. [PMID: 25732419 DOI: 10.1038/ajg.2015.6] [Cited by in Crossref: 170] [Cited by in F6Publishing: 138] [Article Influence: 24.3] [Reference Citation Analysis]
9 Lyu D, Kou G, Li S, Li L, Li B, Zhou R, Yang X, Tian W, Li Y, Zuo X. Digital Spatial Profiling Reveals Functional Shift of Enterochromaffin Cell in Patients With Ulcerative Colitis. Front Cell Dev Biol 2022;10:841090. [DOI: 10.3389/fcell.2022.841090] [Reference Citation Analysis]
10 Magnusson MK, Lasson A, Stridsberg M, Isaksson S, Strid H, Öhman L, Wei J. Faecal secretogranin and chromogranin levels persist over time and are unrelated to disease history and outcome in patients with ulcerative colitis. Cogent Medicine 2018;5:1484602. [DOI: 10.1080/2331205x.2018.1484602] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Eissa N, Hussein H, Hendy GN, Bernstein CN, Ghia JE. Chromogranin-A and its derived peptides and their pharmacological effects during intestinal inflammation. Biochem Pharmacol 2018;152:315-26. [PMID: 29656116 DOI: 10.1016/j.bcp.2018.04.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
12 Li M, Weigmann B. A Novel Pathway of Flavonoids Protecting against Inflammatory Bowel Disease: Modulating Enteroendocrine System. Metabolites 2022;12:31. [PMID: 35050153 DOI: 10.3390/metabo12010031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Shulman RJ, Öhman L, Stridsberg M, Cain K, Simrén M, Heitkemper M. Evidence of increased fecal granins in children with irritable bowel syndrome and correlates with symptoms. Neurogastroenterol Motil 2019;31:e13486. [PMID: 30298961 DOI: 10.1111/nmo.13486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 El-Salhy M, Solomon T, Hausken T, Gilja OH, Hatlebakk JG. Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease. World J Gastroenterol 2017; 23(28): 5068-5085 [PMID: 28811704 DOI: 10.3748/wjg.v23.i28.5068] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]